Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy. Results of their study were published in the Journal for Immunotherapy of Cancer. TIL therapy starts with doctor’s …
RNA sequencing reveals how CD40L boosts TIL therapy by activating B cells
Share.
